IP Library Granted Patent US 10,344,076
Granted Patent B2
US 10,344,076 · App. 15/048,339 · Granted Jul 9, 2019

Means and methods for producing high affinity antibodies

Inventors: Tim Beaumont (Ouderkerk a/d Amstel, NL); Mark Jeroen Kwakkenbos (Amsterdam, NL); Hergen Spits (Amsterdam, NL); Adrianus Quirinus Bakker (Hoorn, NL)
Assignee: AIMM THERAPEUTICS B.V.
C07K16/1027C07K16/00C07K2317/14C07K2317/24C07K2317/56C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,344,076
App. No.
15/048,339
Granted
Jul 9, 2019
Kind
B2
Abstract

The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.

Claims (13)

1. A method of antibody production, the method comprising:

introducing an exogenous nucleic acid molecule encoding Bcl 6 into a B cell;

introducing an exogenous anti-apoptotic nucleic acid molecule into said B cell, thus generating an antibody producing plasmablast-like B cell with functional AID activity;

selecting an antibody producing plasmablast-like B cell that produces an antibody of interest; and

reducing expression and/or activity of AID in said B cell thereby reducing the occurrence of somatic hypermutations in said B-cell.

2. The method according to claim 1 , wherein the expression and/or activity of AID is reduced in said B cell by introduction of a molecule that interferes with the homo- or heterodimerization of E47 and/or E12.

3. The method according to claim 1 , wherein the expression and/or activity of AID is reduced in said B cell by introduction of an exogenous nucleic acid molecule encoding an ID protein.

4. The method according to claim 1 , wherein the expression and/or activity of AID is reduced in said B cell by introduction of an antisense nucleic acid or ribozyme directed against E12 and/or E47.

5. The method according to claim 1 , wherein the expression and/or activity of AID is reduced in said B cell by introduction of a dsRNA molecule that induces E12 or E47 mRNA degradation.

6. The method according to claim 1 , wherein the expression and/or activity of AID is reduced in said B cell by introduction of a zinc-finger protein that has been modified to be able to bind to the promoter region of AID and which is coupled to a transcriptional repressor domain.

7. The method according to claim 1 , wherein the anti-apoptotic nucleic acid comprises a gene of the BCL2 family.

8. The method according to claim 7 , wherein the gene of the BCL2 family is Bcl-xL or Mcl 1, or a functional part thereof.

9. The method according to claim 1 , wherein the B-cell is cultured in the presence of IL21 and CD40L.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: AIMM THERAPEUTICS B.V.
To: KLING BIOTHERAPEUTICS B.V.
Reel/Frame 055711/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2016
From: BEAUMONT, TIM; SPITS, HERGEN; KWAKKENBOS, MARK JEROEN; BAKKER, ADRIANUS QUIRINUS
To: AIMM THERAPEUTICS B.V.
Reel/Frame 037778/0605 →
Priority Claims (1)
EP 09165603 · Jul 15, 2009 · regional
Continuity (3)
Division 13383832 · Jan 31, 2012
Provisional Application 61225882 · Jul 15, 2009
Related Publication 20160194382A1 · Jul 7, 2016